PharmaCyte Biotech, Inc. (PMCB) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001157075 · SEC filings checked Oct 17, 2026
Next report
Dec 17, 2026
Estimated from reporting history (94-day cycle, SEC periodic report filing dates). Not confirmed.
Last close
$0.34
Polygon.io daily close, Oct 16, 2026. End of day, not live.
Trailing diluted EPS
$-2.08
Sum of quarters ending Jul 31, 2026, Apr 30, 2026, Jan 31, 2026, Oct 31, 2025
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jul 31, 2026 | Sep 14, 2026 | $0 | $-5.1M | $-0.54 | Filing |
| Apr 30, 2026 | Jul 29, 2026 | $0 | $-4.4M | $-0.13 | Filing |
| Jan 31, 2026 | Mar 17, 2026 | $0 | $746,860 | $-0.17 | Filing |
| Oct 31, 2025 | Dec 18, 2025 | $0 | $-7.4M | $-1.24 | Filing |
| Jul 31, 2025 | Sep 15, 2025 | $0 | $-8.4M | $-1.23 | Filing |
| Apr 30, 2025 | Aug 11, 2025 | $0 | $11.7M | $2.12 | Filing |
| Jan 31, 2025 | Mar 17, 2025 | $0 | $-3.0M | $-0.44 | Filing |
| Oct 31, 2024 | Dec 13, 2024 | $0 | $-1.5M | $-0.39 | Filing |
What would PharmaCyte Biotech, Inc. have to report for its valuation to change?
Trailing earnings are negative, so a price-to-earnings reverse model does not apply. The model is not shown rather than filled with assumptions.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.